(Q41648614)

English

Efficacy of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in the treatment of patients with hypercholesterolemia: a meta-analysis of clinical trials

scientific article published on July 1997

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

0 references

Efficacy of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in the treatment of patients with hypercholesterolemia: a meta-analysis of clinical trials (English)

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

hypercholesterolemia

0 references

author name string

Kong SX

1

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

Crawford SY

2

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

Gandhi SK

3

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

Seeger JD

4

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

Schumock GT

5

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

Lam NP

6

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

Stubbings J

7

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

Schoen MD

8

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

publication date

1 July 1997

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

Clinical Therapeutics

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

19

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

778-797

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

Cholesterol and mortality. 30 years of follow-up from the Framingham study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980102-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980102-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980102-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Meta-analysis in clinical research

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980102-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Meta-analyses of randomized controlled trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980102-6

7 January 2021

based on heuristic

inferred from DOI database lookup

A multicenter comparative trial of lovastatin and pravastatin in the treatment of hypercholesterolemia. The Lovastatin Pravastatin Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980102-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of the effect of fluvastatin, an hydroxymethyl glutaryl coenzyme A reductase inhibitor, and cholestyramine, a bile acid sequestrant, on lipoprotein particles defined by apolipoprotein composition

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980102-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of lipid-lowering effects of low-dose fluvastatin and conventional-dose gemfibrozil in patients with primary hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980102-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of fluvastatin on intermediate density lipoprotein (remnants) and other lipoprotein levels in hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980102-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of primary hypercholesterolemia: fluvastatin versus bezafibrate

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980102-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Fluvastatin and niacin in hypercholesterolemia: a preliminary report on gender differences in efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980102-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of a low dose-range of fluvastatin (XU 62-320) in the treatment of primary hypercholesterolaemia. A dose-response study in 431 patients. The French-Dutch Fluvastatin Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980102-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of fluvastatin in patients with non-insulin-dependent diabetes mellitus and hyperlipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980102-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of high dose fluvastatin in patients with familial hypercholesterolaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980102-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Fluvastatin for dyslipoproteinemia,with or without concomitant chronic renal insufficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980102-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Low-dose combined therapy with fluvastatin and cholestyramine in hyperlipidemic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980102-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS).

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980102-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980102-6

7 January 2021

based on heuristic

inferred from DOI database lookup

A comparison between lovastatin and gemfibrozil in the treatment of primary hypercholesterolemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980102-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Cholesterol lowering in the elderly. Results of the Cholesterol Reduction in Seniors Program (CRISP) pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980102-6

7 January 2021

based on heuristic

inferred from DOI database lookup

A multicenter comparison of lovastatin and probucol for treatment of severe primary hypercholesterolemia. The Lovastatin Study Group IV

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980102-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of lovastatin on natural killer cell function and other immunological parameters in man.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980102-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison between lovastatin and gemfibrozil in the treatment of primary hypercholesterolemia: the Finnish Multicenter Study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980102-6

7 January 2021

based on heuristic

inferred from DOI database lookup

A multicenter double-blind study comparing lovastatin and gemfibrozil in the treatment of primary hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980102-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of familial hypercholesterolaemia. United Kingdom lipid clinics study of pravastatin and cholestyramine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980102-6

7 January 2021

based on heuristic

inferred from DOI database lookup

The efficacy and safety of pravastatin in patients aged 60 to 85 years with low-density lipoprotein cholesterol > 160 mg/dl

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980102-6

7 January 2021

based on heuristic

inferred from DOI database lookup

The efficacy and safety of pravastatin, compared to and in combination with bile acid binding resins, in familial hypercholesterolaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980102-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. I. A dose-response study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980102-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS)

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980102-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Apolipoprotein(a) polymorphism predicts the increase of Lp(a) by pravastatin in patients with familial hypercholesterolaemia treated with bile acid sequestration

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980102-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): Reduction in atherosclerosis progression and clinical events

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980102-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dl) plus two additional atherosclerotic risk factors. The Pravastatin Multinational Study Group for Cardiac Risk Patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980102-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980102-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of pravastatin in the long-term treatment of elderly patients with hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980102-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of the efficacy, safety and tolerability of simvastatin and pravastatin for hypercholesterolemia. The Simvastatin Pravastatin Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980102-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparative efficacy and tolerability of 5 and 10 mg simvastatin and 10 mg pravastatin in moderate primary hypercholesterolemia. Simvastatin Pravastatin European Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980102-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of familial hypercholesterolaemia: a controlled trial of the effects of pravastatin or cholestyramine therapy on lipoprotein and apolipoprotein levels

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980102-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980102-6

7 January 2021

based on heuristic

inferred from DOI database lookup

The effectiveness and safety of low dose pravastatin in elderly hypertensive hypercholesterolemic subjects on antihypertensive therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980102-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Lipid control with low-dosage simvastatin in patients with moderate hypercholesterolaemia. An Italian multicentre double-blind placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980102-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of simvastatin on Lp(a) concentrations

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980102-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Three-year follow-up of the Oxford Cholesterol Study: assessment of the efficacy and safety of simvastatin in preparation for a large mortality study.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980102-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of simvastatin and probucol in hypercholesterolemia (Simvastatin Multicenter Study Group II)

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980102-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison between morning and evening doses of simvastatin in hyperlipidemic subjects. A double-blind comparative study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980102-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Dose-response of simvastatin in primary hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980102-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety, tolerability, and efficacy of simvastatin and fenofibrate--a multicenter study. Simvastatin-Fenofibrate Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980102-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Expanded clinical evaluation of lovastatin (EXCEL) study: design and patient characteristics of a double-blind, placebo-controlled study in patients with moderate hypercholesterolemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980102-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: two-year efficacy and safety follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980102-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of simvastatin versus gemfibrozil on lipids and glucose control in patients with non-insulin-dependent diabetes mellitus. NIDDM Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980102-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of pravastatin in the treatment of patients with type I or type II diabetes mellitus and hypercholesterolemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980102-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II)

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980102-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of cholesterol lowering on the progression of coronary atherosclerosis in women. A Canadian Coronary Atherosclerosis Intervention Trial (CCAIT) substudy.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980102-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Fluvastatin efficacy and tolerability in comparison and in combination with cholestyramine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980102-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Changes in Lp(a) lipoprotein levels during the treatment of hypercholesterolaemia with simvastatin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980102-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of fluvastatin in patients with non-insulin-dependent diabetes mellitus and hyperlipidemia: preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980102-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacodynamic effects and pharmacokinetics of atorvastatin after administration to normocholesterolemic subjects in the morning and evening

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980102-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980102-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980102-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980102-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Cumulative meta-analysis of therapeutic trials for myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980102-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0149-2918(97)80102-6

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41648614&oldid=1925501622"